Erythropoietin fails to reverse the anemia in mice continuously exposed to tumor necrosis factor-alpha in vivo

U. Clibon, L. Bonewald, J. Caro, G. D. Roodman

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

Tumor necrosis factor-α (TNF) is a monokine produced by activated macrophages that has cytotoxic and cytostatic effects on erythroid progenitor cells. We have recently shown that Chinese hamster ovary cells transfected with the human TNF gene and which constitutively express TNF induced a hypoproliferative anemia, mild thrombocytopenia, and mild leukocytosis when injected into nude mice. We have used this murine model to determine if treatment with recombinant human erythropoietin can prevent or ameliorate the anemia seen with long-term continuous exposure to high concentrations of TNF. Mice bearing TNF-producing tumors became anemic with hematocrits ranging from 30 to 32%. Treatment with recombinant human erythropoietin (100-1000 U/kg body weight three times per week) increased the reticulocyte counts initially in mice bearing TNF-producing tumors but failed to reverse the anemia seen in these animals. Erythropoietin did not significantly increase the number of marrow erythroid colony-forming units (CFU-E) or erythroid burst-forming units (BFU-E) in mice bearing TNF-producing tumors. The data suggest that erythropoietin could not sufficiently overcome the decreased number of erythroid progenitors in mice bearing tumors producing high levels of TNF to correct their anemia.

Original languageEnglish (US)
Pages (from-to)438-441
Number of pages4
JournalExperimental Hematology
Volume18
Issue number5
StatePublished - Jul 2 1990
Externally publishedYes

    Fingerprint

Keywords

  • Anemia
  • Erythroid progenitors
  • Erythropoietin
  • TNF

ASJC Scopus subject areas

  • Molecular Biology
  • Hematology
  • Genetics
  • Cell Biology
  • Cancer Research

Cite this